European Medicines Agency Validates Biosplice's Application for Knee Osteoarthritis Treatment

The European Medicines Agency (EMA) has validated Biosplice's marketing authorization application for lorecivivint (LOR), a first-in-class small-molecule inhibitor, for the treatment of knee osteoarthritis. This validation, which occurred on September 30, 2026, marks the beginning of the EMA's centralized review process. LOR is also under regulatory assessment in the United Kingdom.